Sign Up Today and Learn More About Antiva Biosciences Stock
Invest in or calculate the value of your shares in Antiva Biosciences or other pre-IPO companies through EquityZen's platform.
Antiva Biosciences Stock (ANBI)
Antiva Biosciences is a biopharmaceutical company developing therapeutics for the treatment of diseases caused by HPV infection.
About Antiva Biosciences Stock
Founded
2012
Headquarters
Del Mar, CA, US
Industries
Software, Artificial Intelligence, Data and Analytics
Antiva Biosciences Press Mentions
Stay in the know about the latest news on Antiva Biosciences
Treatment of hpv infection
patents • Feb 15, 2025
COMPOSITIONS AND PHARMACEUTICAL FORMS FOR THE TREATMENT OF HPV INFECTION AND …
patents • Feb 15, 2025
Human Papillomavirus Market is Projected to Boost at a Moderate Growth Rate During the Study Period (2020–2034) | DelveInsight
globenewswire • Nov 19, 2024
Oruka Therapeutics Announces Key Additions to Leadership Team and Board of Directors
finance • Aug 03, 2024
Antiva Biosciences Announces Formation of Scientific and Development Advisory Board
prnewswire • Jun 25, 2024
Antiva Biosciences Management
Leadership team at Antiva Biosciences
Board member
Dr. Brian Goodman
Vice President of Pharmaceutical Development and Manufacturing
Surya Gadiraju
Join now and verify your accreditation status to gain access to:
- Antiva Biosciences Current Valuation
- Antiva Biosciences Stock Price
- Antiva Biosciences Management
- Available deals in Antiva Biosciences and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Antiva Biosciences Cap Table and Funding History by Share Class and Liquidity Preferences
- Antiva Biosciences Revenue and Financials
- Antiva Biosciences Highlights
- Antiva Biosciences Business Model
- Antiva Biosciences Risk Factors
- Antiva Biosciences Research Report from SACRA Research
Trading Antiva Biosciences Stock
How to invest in Antiva Biosciences stock?
Accredited investors can buy pre-IPO stock in companies like Antiva Biosciences through EquityZen funds. These investments are made available by existing Antiva Biosciences shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Antiva Biosciences stock?
Shareholders can sell their Antiva Biosciences stock through EquityZen's private company marketplace. EquityZen's network includes over 350K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 45K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
